Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by the scarring and thickening of lung tissue.
Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by the scarring and thickening of lung tissue. This scarring, also known as fibrosis, makes the lungs stiff and reduces their ability to expand and contract properly. As the fibrosis worsens over time, it becomes increasingly difficult for oxygen to pass from the lungs into the bloodstream, leading to shortness of breath. The causes of PF are diverse and often remain unknown (idiopathic pulmonary fibrosis). Known causes and associated conditions include exposure to certain environmental pollutants, some medications, radiation therapy, and connective tissue diseases like rheumatoid arthritis and scleroderma. Symptoms typically develop gradually and include shortness of breath (initially during exertion and later at rest), a dry, hacking cough, fatigue, and unexplained weight loss. Unfortunately, there is currently no cure for pulmonary fibrosis, and the scarring is irreversible. However, various treatments are available to help manage symptoms, slow down the progression of the disease, and improve quality of life. These include medications, pulmonary rehabilitation to improve exercise tolerance and breathing techniques, and in some cases, lung transplantation. Early diagnosis and appropriate management are crucial for individuals living with pulmonary fibrosis.
The Systems Architecture of Pulmonary Fibrosis is published as a web based tool open to public . Click below to interact with the Systems Architecture
A peer-reviewed publication resulting from the Pulmonary Fibrosis Initiative will be published to the benefit of community.
In this phase, the Pulmonary Fibrosis Initiative will conduct in silico modeling to identify and test the efficacy of natural compounds against the Fibrosis, Inflammation and Apoptosis. This phase is yet to begin.
In this phase, combination screening will be performed to identify potential ingredient/compounds that target the biological process implicated in Pulmonary Fibrosis pathogenesis. This phase is yet to begin
The Open Science Institute® through its Pulmonary Fibrosis Initiative is moving towards getting patents for a revolutionary molecule that effectively combats pulmonary fibrosis disease, contributing breakthrough real solutions to society worldwide.
The Pulmonary Fibrosis Initiative plans to discover, develop, license and manufacture proprietary nutraceuticals to support treatment of Pulmonary fibrosis. Support our mission to bring this innovation to those who need it most. Please support this phase by donating to the Pulmonary Fibrosis Initiative